Clinical trials: Healthy Adult Immune Response
Healthy Adults
Effect of Bismuth Subsalicylate on the Gut Microbiome and Host Response in Healthy Adults
Background: Many kinds of good or normal bacteria live on your skin and inside your stomach and intestines (gut). These bacteria are important to your health.
- Trial name
- NCT05930197
- Testing
- Bismuth subsalicylate
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Safety of and Immune Response to Polyvalent HIV-1 Vaccine in HIV Uninfected Adults
This study will evaluate the safety of and immune response to a new HIV vaccine. The vaccine in this trial uses pieces of HIV DNA and HIV proteins. The vaccine itself cannot cause HIV infection or AIDS.
- Trial name
- NCT00061243
- Testing
- HIV-1 DNA vaccine with protein vaccine boost
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
West Nile Fever
Phase I Study of West Nile Virus Vaccine
This study will test the safety of an experimental vaccine for preventing West Nile virus infection. The virus is spread mainly by mosquito bites.
- Trial name
- NCT00300417
- Testing
- VRC-WNVDNA020-00-VP
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Human
A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults
The purpose of this study is to find and confirm the dose and asses the reactogenicity, safety and immune response of GlaxoSmithKline's (GSK) messenger RNA (mRNA)-based multivalent seasonal influenza vaccine (GSK4382276A)…
- Trial name
- NCT05823974
- Testing
- F2C22C/DL001Z, F2B22A/DL001Z, F2B22B/DL001Z
- Where
- 41 sites in United States, Belgium and 2 more
- Volunteers
- 1,275 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pertussis (Whooping Cough)
Establishing a Controlled Human Infection Model of Pertactin-deficient Bordetella Pertussis
The overall goal of this study is to establish a PRN-deficient pertussis Controlled Human Infection Model (CHIM) that represents currently circulating isolates, in the context of a North American exposure (vaccination and…
- Trial name
- NCT06827470
- Testing
- Biological: Bordetella pertussis J820
- Where
- Canada
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Dalhousie University
Influenza
Bone Marrow and Peripheral Blood Immune Responses Study
The purpose of this study is to evaluate the immune response of the killed flu vaccine in healthy subjects. Participants in this study are considered to be healthy volunteers.
- Trial name
- NCT05616546
- Testing
- Influenza Vaccine
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Emory University
Salmonella Infections
A Study to Evaluate the Safety, Reactogenicity, and Immune Response of the GSK Vaccines Institute for Global Health (GVGH) Quadrivalent Pan-Salmonella Vaccine With and Without Alum in Healthy Young Adults
The current clinical study will evaluate the GVGH Quadrivalent Pan-Salmonella vaccine for the first time in healthy adults in Africa.
- Trial name
- NCT07663032
- Testing
- Pan-Salmonella-with-Alum (Low dose) vaccine, Pan-Salmonella-with-Alum (Full dose) vaccine, Pan-Salmonella-without-Alum (Low dose) vaccine
- Where
- South Africa
- Volunteers
- 196 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Ebola Sudan Virus Disease
Monovalent Chimpanzee Adenoviral-Vectored Sudan Ebolavirus Vaccine in Healthy Adults
A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral-Vectored Sudan Ebolavirus Vaccine in Healthy Adults
- Trial name
- NCT06036602
- Testing
- cAD3-Sudan Ebolavirus Vaccine
- Where
- 2 sites in Kenya, Uganda
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Albert B. Sabin Vaccine Institute
COVID-19
A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy Adults
The purpose of this study is to evaluate the safety, reactogenicity and immune responses of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA-CR-04 vaccine construct when administered in healthy adults…
- Trial name
- NCT05972993
- Testing
- mRNA-CR-04 vaccine 10μg, mRNA-CR-04 vaccine 30μg, mRNA-CR-04 vaccine 100μg
- Where
- 4 sites in United States
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
EBV, Epstein-Barr Virus Infection
Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection
Background: Epstein-Barr virus (EBV) is the primary cause of infectious mononucleosis, commonly known as mono. EBV infects more than 90% of the world s population.
- Conditions
- EBV, Epstein-Barr Virus Infection, Infectious Mononucleosis, Mono
- Trial name
- NCT06908096
- Testing
- EBV gp350-ferritin vaccine with ALFQ adjuvant, EBV gH/gL/gp42-ferritin nanoparticle vaccine with ALFQ adjuvant
- Where
- United States
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis B Vaccination
Hepatitis B Vaccine in Seniors
The first purpose of this study is to test the body's protective reaction (making antibodies) to a licensed hepatitis B vaccine (Recombivax-HB) after it is injected either in the arm fat or muscle.
- Trial name
- NCT04162223
- Testing
- Subcutaneous fat injection of Recombivax-HB, Intramuscular injection of Recombivax-HB
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Herpes Zoster
A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine
The aim of this study was to evaluate the immune response and safety of both GlaxoSmithKline Biologicals SA's (GSK's) herpes zoster (HZ) subunit (su) vaccine in healthy adults 50 years of age (YOA) and older and quadrivalent…
- Trial name
- NCT05047770
- Testing
- HZ/su, Flu D-QIV, mRNA-1273
- Where
- 46 sites in United States
- Volunteers
- 2,013 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Volunteer, Immune Response
LC-Plasma on Immune Response and Reducing Symptoms of Upper Respiratory Infectious Diseases
The goal of this study is to evaluate the effects of LC-Plasma on the innate and acquired immune systems, including the activation of pDCs, which play a role in virus elimination, as well as to assess its efficacy in reducing…
- Trial name
- NCT06837961
- Testing
- LC-Plasma
- Where
- Australia
- Volunteers
- 241 people, healthy volunteers welcome
- Sponsor
- RDC Clinical Pty Ltd
Hepatitis B
A Study to Characterise Immune Responses Following Immunisations With "Fendrix" or "Engerix B" Hepatitis B Vaccines
The purpose of this study is to generate an exploratory training set of data and to identify predictive biomarkers (a measurable biological response that predicts something) of innate and adaptive responses to immunisation of two…
- Trial name
- NCT02032160
- Testing
- Engerix B IM injection - 20ug, Fendrix IM injection - 20ug
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Surrey
Influenza, Influenza, Human
Kinetics of the Immune Response to Inactivated Influenza Vaccine in Healthy Adults
The purpose of this study is to evaluate the body's immune response at different time points to an FDA-approved seasonal influenza vaccine.
- Conditions
- Influenza, Influenza, Human, Vaccine Reaction, Influenza A
- Trial name
- KIRV (NCT03743688)
- Testing
- Influenza Vaccine Recipients
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Adult, Healthy Participants
A Study to Learn About the Safety and Immune Responses of RSVpreF in Older Adults
The purpose of this study is to learn about the safety, tolerability, and immune response of the RSVpreF vaccine in healthy older adults. Participants will take part in this study for about 6 months.
- Trial name
- NCT07819097
- Testing
- RSVpreF
- Where
- 15 sites in United States, China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Pfizer
HIV Infections
Safety of and Immune Response to an Experimental HIV Vaccine (VRC-HIVADV014-00-VP) in HIV Uninfected Adults
The purpose of this study is to determine the safety of and immune response to an experimental HIV vaccine in HIV uninfected individuals.
- Trial name
- NCT00119873
- Testing
- VRC-HIVADV014-00-VP
- Where
- 3 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Immune Tolerance, Viral Infection
Immune Responses With Reduxium
Reduxium is a dietary supplement that provides immune support. This natural compound is orally-ingested in the form of droplets in water to boost the immune system and control inflammation.
- Trial name
- NCT04525456
- Testing
- Reduxium
- Where
- 3 sites in Singapore
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Ogevity Therapeutics, Inc.
Tuberculosis
Leukapheresis Sampling for Immune Responses After BCG Vaccination in BCG-naïve Healthy Adults in the US
The objective of this protocol is to obtain biological samples through leukapheresis and cryopreservation of cells for the future study, by in vitro assay, of immune responses after one dose of BCG in BCG-naïve healthy adults.
- Trial name
- NCT02413502
- Testing
- BCG
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Aeras
HIV Prevention
VRC 605: Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered Intravenously or Subcutaneously to Healthy Adults
Background: Human immunodeficiency virus (HIV) is a global health threat. The body uses antibodies to fight infection. VRC07-523LS is an antibody directed against HIV.
- Trial name
- NCT03015181
- Testing
- VRC-HIVMAB075-00-AB
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)